Skip to main content
PMC home page
Sarcoma logoLink to Sarcoma
. 2000 Dec 22;4(4):151–160. doi: 10.1155/2000/126837

Intensified Adjuvant IFADIC Chemotherapy for Adult Soft Tissue Sarcoma: A Prospective Randomized Feasibility Trial

Thomas Brodowicz 1, Eva Schwameis 2, Joachim Widder 3, Gabriele Amann 4, Christoph Wiltschke 1,*, Martin Dominkus 2, Reinhard Windhager 2, Peter Ritschl 5, Richard Pötter 3, Rainer Kotz 2, Christoph C Zielinski 1,6
PMCID: PMC2395444  PMID: 18521295

Abstract

Purpose. The present prospective randomized adjuvant trial was carried out to compare the toxicity, feasibility and efficacy of augmented chemotherapy added to hyperfractionated accelerated radiotherapy after wide or marginal resection of grade 2 and grade 3 soft tissue sarcoma (STS).

Patients and methods. Fifty-nine patients underwent primary surgery by wide or marginal excision and were subsequently randomized to receive radiotherapy alone or under the addition of six courses of ifosfamide (1500 mg/m2 , days 1–4), dacarbazine (DTIC) (200 mg/m2 , days 1–4) and doxorubicin (25 mg/m2 , days 1–2) administered in 14-day-intervals supported by granulocyte-colony stimulating factor (30 × 106 IU/day, s.c.) on days 5–13. According to the randomization protocol, 28 patients received radiotherapy only, whereas 31 patients were treated with additional chemotherapy.

Results. The relative ifosfamide–doxorubicin–DTIC (IFADIC) dose intensity achieved was 93%. After a mean observation period of 41±19.7 months (range, 8.1–84 months), 16 patients (57%) in the control group versus 24 patients (77%) in the chemotherapy group were free of disease (p>0.05).Within the control group, tumor relapses occurred in 12 patients (43%;six patients with distant metastases, two with local relapse, four with both) versus seven patients (23%; five patients with distant metastases, one with local recurrence, one with both) from the chemotherapy group. Relapse-free survival (RFS) (p=0.1), time to local failure (TLF) (p=0.09), time to distant failure (TDF) (p=0.17) as well as overall survival (OS) (p=0.4) did not differ significantly between the two treatment groups. Treatment-related toxicity was generally mild in both treatment arms.

Conclusions. We conclude that the safety profile of intensified IFADIC added to radiotherapy was manageable and tolerable in the current setting. Inclusion of intensified IFADIC was not translated into a significant benefit concerning OS, RFS, TLF andTDF as compared with radiotherapy only, although a potential benefit of chemotherapy for grade 3 STS patients needs to be validated in prospective randomized trials including larger patient numbers.

Full Text

The Full Text of this article is available as a PDF (168.1 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alho A., Alvegård T. A., Berlin O., Ranstam J., Rydholm A., Röser B., Stener B. Surgical margin in soft tissue sarcoma. The Scandinavian Sarcoma Group experience. Acta Orthop Scand. 1989 Dec;60(6):687–692. doi: 10.3109/17453678909149605. [DOI] [PubMed] [Google Scholar]
  2. Alvegård T. A., Sigurdsson H., Mouridsen H., Solheim O., Unsgaard B., Ringborg U., Dahl O., Nordentoft A. M., Blomqvist C., Rydholm A. Adjuvant chemotherapy with doxorubicin in high-grade soft tissue sarcoma: a randomized trial of the Scandinavian Sarcoma Group. J Clin Oncol. 1989 Oct;7(10):1504–1513. doi: 10.1200/JCO.1989.7.10.1504. [DOI] [PubMed] [Google Scholar]
  3. Antman K. H., Elias A. D. Chemotherapy of advanced soft-tissue sarcomas. Semin Surg Oncol. 1988;4(1):53–58. doi: 10.1002/ssu.2980040111. [DOI] [PubMed] [Google Scholar]
  4. Antman K., Crowley J., Balcerzak S. P., Rivkin S. E., Weiss G. R., Elias A., Natale R. B., Cooper R. M., Barlogie B., Trump D. L. An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. J Clin Oncol. 1993 Jul;11(7):1276–1285. doi: 10.1200/JCO.1993.11.7.1276. [DOI] [PubMed] [Google Scholar]
  5. Bramwell V., Rouesse J., Steward W., Santoro A., Schraffordt-Koops H., Buesa J., Ruka W., Priario J., Wagener T., Burgers M. Adjuvant CYVADIC chemotherapy for adult soft tissue sarcoma--reduced local recurrence but no improvement in survival: a study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol. 1994 Jun;12(6):1137–1149. doi: 10.1200/JCO.1994.12.6.1137. [DOI] [PubMed] [Google Scholar]
  6. Bui B. N., Chevallier B., Chevreau C., Krakowski I., Peny A. M., Thyss A., Maugard-Louboutin C., Cupissol D., Fargeot P., Bonichon F. Efficacy of lenograstim on hematologic tolerance to MAID chemotherapy in patients with advanced soft tissue sarcoma and consequences on treatment dose-intensity. J Clin Oncol. 1995 Oct;13(10):2629–2636. doi: 10.1200/JCO.1995.13.10.2629. [DOI] [PubMed] [Google Scholar]
  7. Chang A. E., Kinsella T., Glatstein E., Baker A. R., Sindelar W. F., Lotze M. T., Danforth D. N., Jr, Sugarbaker P. H., Lack E. E., Steinberg S. M. Adjuvant chemotherapy for patients with high-grade soft-tissue sarcomas of the extremity. J Clin Oncol. 1988 Sep;6(9):1491–1500. doi: 10.1200/JCO.1988.6.9.1491. [DOI] [PubMed] [Google Scholar]
  8. DeVita V. T. Dose-response is alive and well. J Clin Oncol. 1986 Aug;4(8):1157–1159. doi: 10.1200/JCO.1986.4.8.1157. [DOI] [PubMed] [Google Scholar]
  9. Dunst J., Jürgens H., Sauer R., Pape H., Paulussen M., Winkelmann W., Rübe C. Radiation therapy in Ewing's sarcoma: an update of the CESS 86 trial. Int J Radiat Oncol Biol Phys. 1995 Jul 15;32(4):919–930. doi: 10.1016/0360-3016(95)00016-r. [DOI] [PubMed] [Google Scholar]
  10. Edmonson J. H., Fleming T. R., Ivins J. C., Burgert E. O., Jr, Soule E. H., O'Connell M. J., Sim F. H., Ahmann D. L. Randomized study of systemic chemotherapy following complete excision of nonosseous sarcomas. J Clin Oncol. 1984 Dec;2(12):1390–1396. doi: 10.1200/JCO.1984.2.12.1390. [DOI] [PubMed] [Google Scholar]
  11. Edmonson J. H., Ryan L. M., Blum R. H., Brooks J. S., Shiraki M., Frytak S., Parkinson D. R. Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. J Clin Oncol. 1993 Jul;11(7):1269–1275. doi: 10.1200/JCO.1993.11.7.1269. [DOI] [PubMed] [Google Scholar]
  12. Eilber F. R., Giuliano A. E., Huth J. F., Morton D. L. A randomized prospective trial using postoperative adjuvant chemotherapy (adriamycin) in high-grade extremity soft-tissue sarcoma. Am J Clin Oncol. 1988 Feb;11(1):39–45. doi: 10.1097/00000421-198802000-00009. [DOI] [PubMed] [Google Scholar]
  13. Elias A., Ryan L., Sulkes A., Collins J., Aisner J., Antman K. H. Response to mesna, doxorubicin, ifosfamide, and dacarbazine in 108 patients with metastatic or unresectable sarcoma and no prior chemotherapy. J Clin Oncol. 1989 Sep;7(9):1208–1216. doi: 10.1200/JCO.1989.7.9.1208. [DOI] [PubMed] [Google Scholar]
  14. Frei E., 3rd, Canellos G. P. Dose: a critical factor in cancer chemotherapy. Am J Med. 1980 Oct;69(4):585–594. doi: 10.1016/0002-9343(80)90472-6. [DOI] [PubMed] [Google Scholar]
  15. Gherlinzoni F., Bacci G., Picci P., Capanna R., Calderoni P., Lorenzi E. G., Bernini M., Emiliani E., Barbieri E., Normand A. A randomized trial for the treatment of high-grade soft-tissue sarcomas of the extremities: preliminary observations. J Clin Oncol. 1986 Apr;4(4):552–558. doi: 10.1200/JCO.1986.4.4.552. [DOI] [PubMed] [Google Scholar]
  16. Gustafson P. Soft tissue sarcoma. Epidemiology and prognosis in 508 patients. Acta Orthop Scand Suppl. 1994 Jun;259:1–31. [PubMed] [Google Scholar]
  17. Le Cesne A., Judson I., Crowther D., Rodenhuis S., Keizer H. J., Van Hoesel Q., Blay J. Y., Frisch J., Van Glabbeke M., Hermans C. Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: A trial of the European Organization for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group. J Clin Oncol. 2000 Jul;18(14):2676–2684. doi: 10.1200/JCO.2000.18.14.2676. [DOI] [PubMed] [Google Scholar]
  18. Mazanet R., Antman K. H. Adjuvant therapy for sarcomas. Semin Oncol. 1991 Dec;18(6):603–612. [PubMed] [Google Scholar]
  19. Mertens W. C., Bramwell V. H. Adjuvant chemotherapy in the treatment of soft-tissue sarcoma. Clin Orthop Relat Res. 1993 Apr;(289):81–93. [PubMed] [Google Scholar]
  20. O'Bryan R. M., Baker L. H., Gottlieb J. E., Rivkin S. E., Balcerzak S. P., Grumet G. N., Salmon S. E., Moon T. E., Hoogstraten B. Dose response evaluation of adriamycin in human neoplasia. Cancer. 1977 May;39(5):1940–1948. doi: 10.1002/1097-0142(197705)39:5<1940::aid-cncr2820390505>3.0.co;2-0. [DOI] [PubMed] [Google Scholar]
  21. Omura G. A., Blessing J. A., Major F., Lifshitz S., Ehrlich C. E., Mangan C., Beecham J., Park R., Silverberg S. A randomized clinical trial of adjuvant adriamycin in uterine sarcomas: a Gynecologic Oncology Group Study. J Clin Oncol. 1985 Sep;3(9):1240–1245. doi: 10.1200/JCO.1985.3.9.1240. [DOI] [PubMed] [Google Scholar]
  22. Savarese D. M., Hsieh C., Stewart F. M. Clinical impact of chemotherapy dose escalation in patients with hematologic malignancies and solid tumors. J Clin Oncol. 1997 Aug;15(8):2981–2995. doi: 10.1200/JCO.1997.15.8.2981. [DOI] [PubMed] [Google Scholar]
  23. Steward W. P., Verweij J., Somers R., Spooner D., Kerbrat P., Clavel M., Crowther D., Rouesse J., Tursz T., Tueni E. Granulocyte-macrophage colony-stimulating factor allows safe escalation of dose-intensity of chemotherapy in metastatic adult soft tissue sarcomas: a study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol. 1993 Jan;11(1):15–21. doi: 10.1200/JCO.1993.11.1.15. [DOI] [PubMed] [Google Scholar]
  24. Suit H. D., Mankin H. J., Wood W. C., Gebhardt M. C., Harmon D. C., Rosenberg A., Tepper J. E., Rosenthal D. Treatment of the patient with stage M0 soft tissue sarcoma. J Clin Oncol. 1988 May;6(5):854–862. doi: 10.1200/JCO.1988.6.5.854. [DOI] [PubMed] [Google Scholar]
  25. Suit H. D. The George Edelstyn memorial lecture: radiation in the management of malignant soft tissue tumours. Clin Oncol (R Coll Radiol) 1989 Sep;1(1):5–10. doi: 10.1016/s0936-6555(89)80003-2. [DOI] [PubMed] [Google Scholar]
  26. Van Glabbeke M., van Oosterom A. T., Oosterhuis J. W., Mouridsen H., Crowther D., Somers R., Verweij J., Santoro A., Buesa J., Tursz T. Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing first-line regimens--a European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. J Clin Oncol. 1999 Jan;17(1):150–157. doi: 10.1200/JCO.1999.17.1.150. [DOI] [PubMed] [Google Scholar]
  27. Williams S. D. High dose therapy in germ cell tumors: when, what, and how much? Ann Oncol. 1992 Dec;3(10):780–781. doi: 10.1093/oxfordjournals.annonc.a058095. [DOI] [PubMed] [Google Scholar]
  28. Yap B. S., Baker L. H., Sinkovics J. G., Rivkin S. E., Bottomley R., Thigpen T., Burgess M. A., Benjamin R. S., Bodey G. P. Cyclophosphamide, vincristine, adriamycin, and DTIC (CYVADIC) combination chemotherapy for the treatment of advanced sarcomas. Cancer Treat Rep. 1980 Jan;64(1):93–98. [PubMed] [Google Scholar]

Articles from Sarcoma are provided here courtesy of Wiley

RESOURCES